-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Brii Biosciences and VBI Vaccines announced today that the immunotherapy BRII-179 (VBI-2601) under investigation jointly developed by the two parties has been obtained in a phase 1b/2a clinical trial for the treatment of patients with chronic hepatitis B virus (HBV) infection Positive results
The press release pointed out that the test data was announced at the European Association for the Study of the Liver (EASL) International Liver Conference (ILC) 2021 and has been selected as the "ILC Best" summary, which highlights the most noteworthy research in this year's scientific report
Hepatitis B is one of the most important infectious disease threats in the world, with more than 290 million people infected worldwide
VBI-2601 (BRII-179) is an innovative HBV immunotherapy based on recombinant protein.
In this clinical trial, 49 non-cirrhotic patients with chronic hepatitis B were treated with nucleoside analogs (NUC) and received low-dose or high-dose VBI-2601 (BRII-179) treatment, with or without Interferon-α (IFN-α) treatment
The main findings of the experiment include:
All doses of BRII-179 (VBI-2601) combined with and without low-dose IFN-α therapy showed good tolerability, and no significant adverse events were found
Note: The original text has been deleted
Reference materials:
[1] Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021.
